JP2017514867A5 - - Google Patents

Download PDF

Info

Publication number
JP2017514867A5
JP2017514867A5 JP2016566786A JP2016566786A JP2017514867A5 JP 2017514867 A5 JP2017514867 A5 JP 2017514867A5 JP 2016566786 A JP2016566786 A JP 2016566786A JP 2016566786 A JP2016566786 A JP 2016566786A JP 2017514867 A5 JP2017514867 A5 JP 2017514867A5
Authority
JP
Japan
Prior art keywords
group
alkyl
optionally substituted
heterocyclyl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016566786A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017514867A (ja
JP6479854B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2015/059453 external-priority patent/WO2015169677A1/en
Publication of JP2017514867A publication Critical patent/JP2017514867A/ja
Publication of JP2017514867A5 publication Critical patent/JP2017514867A5/ja
Application granted granted Critical
Publication of JP6479854B2 publication Critical patent/JP6479854B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016566786A 2014-05-07 2015-04-30 医薬組成物のためのスルホキシイミン置換キナゾリン Expired - Fee Related JP6479854B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14167373.1 2014-05-07
EP14167373 2014-05-07
PCT/EP2015/059453 WO2015169677A1 (en) 2014-05-07 2015-04-30 Sulfoximine substituted quinazolines for pharmaceutical compositions

Publications (3)

Publication Number Publication Date
JP2017514867A JP2017514867A (ja) 2017-06-08
JP2017514867A5 true JP2017514867A5 (enExample) 2018-09-20
JP6479854B2 JP6479854B2 (ja) 2019-03-06

Family

ID=50639371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016566786A Expired - Fee Related JP6479854B2 (ja) 2014-05-07 2015-04-30 医薬組成物のためのスルホキシイミン置換キナゾリン

Country Status (7)

Country Link
US (1) US10167296B2 (enExample)
EP (1) EP3140300B1 (enExample)
JP (1) JP6479854B2 (enExample)
AU (1) AU2015257917C1 (enExample)
CA (1) CA2944103A1 (enExample)
ES (1) ES2749186T3 (enExample)
WO (1) WO2015169677A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170066778A1 (en) * 2015-09-04 2017-03-09 Aunova Medchem LLC Solubility for target compounds
WO2017165908A1 (en) * 2016-03-31 2017-10-05 South Australian Health And Medical Research Institute Limited Method of inhibiting high fat diet-related conditions

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19712960A1 (de) 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
SE0102147D0 (sv) 2001-06-18 2001-06-18 Pharmacia Ab New methods
DE60238929D1 (de) 2001-10-29 2011-02-24 Boehringer Ingelheim Int Mnk-kinase-homologe proteine, die an der regulierung der energiehomöostase und dem organellen metabolismus beteiligt sind
GB0315587D0 (en) 2003-07-03 2003-08-13 Univ Dundee Anti-inflammatory assay and compounds
CN1942442B (zh) 2004-04-08 2012-10-31 美国陶氏益农公司 杀虫用n-取代亚磺酰亚胺
EP1746099A1 (en) 2004-12-23 2007-01-24 DeveloGen Aktiengesellschaft Mnk1 or Mnk2 inhibitors
EP1899353A1 (en) * 2005-06-22 2008-03-19 DeveloGen Aktiengesellschaft Thienopyrimidines for pharmaceutical compositions
BRPI0709007A2 (pt) 2006-03-09 2011-06-21 Pharmacopeia Inc inibidores de 8-heteroarilpurina mnk2 para tratamento de distúrbios metabólicos
CA2651898A1 (en) * 2006-04-07 2007-10-18 Develogen Aktiengesellschaft Thienopyrimidines having mnk1/mnk2 inhibiting activity for pharmaceutical compositions
RU2009101911A (ru) 2006-06-22 2010-07-27 Биовитрум Аб (Пабл) (Se) Производные пиридина и пиразина в качестве ингибиторов mnk-киназы
EP1889847A1 (en) * 2006-07-10 2008-02-20 DeveloGen Aktiengesellschaft Pyrrolopyrimidines for pharmaceutical compositions
JP2010527951A (ja) * 2007-05-24 2010-08-19 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト キナーゼ阻害剤としての新規なスルホキシイミン置換型キノリン及びキナゾリン誘導体
AU2009286734A1 (en) * 2008-08-26 2010-03-04 Boehringer Ingelheim International Gmbh Thienopyrimidines for pharmaceutical compositions
TW201102391A (en) 2009-03-31 2011-01-16 Biogen Idec Inc Certain substituted pyrimidines, pharmaceutical compositions thereof, and methods for their use
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
UY33245A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
BR112012021364A2 (pt) * 2010-02-26 2016-10-25 Boehringer Ingelheim Int "compostos cicloalquila contendo tienopirimidinas e composições farmacêuticas".
UY33241A (es) * 2010-02-26 2011-09-30 Boehringer Ingelheim Int ?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
US9170933B2 (en) * 2010-06-28 2015-10-27 International Business Machines Corporation Wear-level of cells/pages/sub-pages/blocks of a memory
AR088082A1 (es) 2011-10-13 2014-05-07 Lilly Co Eli Moduladores selectivos del receptor androgeno
HK1206723A1 (en) 2012-05-21 2016-01-15 Bayer Pharma Aktiengesellschaft Thienopyrimidines
TW201412740A (zh) * 2012-09-20 2014-04-01 Bayer Pharma AG 經取代之吡咯并嘧啶胺基苯并噻唑酮
WO2014048869A1 (en) * 2012-09-26 2014-04-03 Bayer Pharma Aktiengesellschaft Substituted indazol-pyrrolopyrimidines useful in the treatment of hyperproliferative diseases
JP6306035B2 (ja) 2012-11-09 2018-04-04 エヴォテック・インターナショナル・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＥｖｏｔｅｃ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ 医薬組成物のためのスルホキシミン置換キナゾリン
ES2653419T3 (es) * 2013-02-01 2018-02-07 Bayer Pharma Aktiengesellschaft Pirazolopirimidinilamino-indazoles sustituidos
EP3013805B1 (en) 2013-06-28 2018-02-21 Evotec International GmbH Sulfoximine substituted quinazolines and their use as mnk1 and/or mnk2 kinase inhibitors
ES2693520T3 (es) * 2013-12-04 2018-12-12 Evotec International Gmbh Quinazolinas sustituidas con sulfoximina para composiciones farmacéuticas

Similar Documents

Publication Publication Date Title
ES3036123T3 (en) Heterocyclic rip1 kinase inhibitors
CA2903288C (en) N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities
JP7145931B2 (ja) 化合物の結晶多形、その製造方法及び用途
CA3142069A1 (en) Aurora kinase inhibitor and use thereof
JP2016121196A5 (enExample)
JP2018515495A5 (enExample)
JP2016512823A5 (enExample)
AU2014234906B2 (en) Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors
JP2016519165A5 (enExample)
AU2015335783B2 (en) Tricyclic atropisomer compounds
EP3227270A2 (en) Heterocyclic derivatives and use thereof
JP2015508092A5 (enExample)
JP2017527598A5 (enExample)
CN110776481B (zh) 一类双阳离子化合物及其制备方法和用途
WO2017084640A1 (zh) 一种含氮杂环化合物及其制备方法与在抑制激酶活性中的应用
JP2019532067A5 (enExample)
JP2015502371A5 (enExample)
WO2017083756A1 (en) Heterocyclic compounds for the treatment of disease
US20190202826A1 (en) Phosphotidylinositol 3-Kinase Inhibitors
WO2018133875A1 (zh) Jak酶抑制剂及其制备方法和用途
JP2025540714A (ja) Ｌｐａ受容体活性と関連する状態を処置するための化合物および組成物
JP2017514867A5 (enExample)
JP2020517676A5 (enExample)
WO2023160672A1 (en) Compounds and compositions for treating conditions associated with lpa receptor activity
CN110437235B (zh) 3-酰胺氮杂吲哚类化合物作为肥大细胞调节剂及其制备方法和用途